Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser) Long‐term hair regrowth ≥ 75% ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone) Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 1.67 [0.96, 2.88] | 2 studies · 80 participants | Low |
Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone) Incidence of serious adverse events · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | 4 studies · 154 participants | Very low |
Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | RR 13.84 [0.87, 219.76] | 1 study · 231 participants | Very low |
Corticosteroids vs no corticosteroids Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | RR 2.55 [0.72, 9.03] | 2 studies · 56 participants | Very low |
Intravenous immunoglobulin (IVIG) vs no IVIG Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs no corticosteroids Time to complete re‐epithelialisation – not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs corticosteroids Disease‐specific mortality · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs corticosteroids Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs corticosteroids Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs corticosteroids Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs corticosteroids Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs corticosteroids Disease‐specific mortality (time to · treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | RR 0.51 [0.16, 1.63] | 1 study · 91 participants | Low |
Etanercept vs corticosteroids Time to complete re‐epithelialisation ‐ not reported · treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs corticosteroids Intensive care unit (ICU) length of stay ‐ not reported · treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs corticosteroids Total hospital length of stay ‐ not reported · treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs no corticosteroids Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs corticosteroids Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported (see comments) · treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs no corticosteroids Total hospital length of stay – not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs intravenous immunoglobulin (IVIG) Disease‐specific mortality (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | RR 0.13 [0.02, 0.98] | 1 study · 22 participants | Very low |
Cyclosporin vs intravenous immunoglobulin (IVIG) Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs intravenous immunoglobulin (IVIG) Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs intravenous immunoglobulin (IVIG) Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs intravenous immunoglobulin (IVIG) Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs cyclosporin Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs cyclosporin Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs cyclosporin Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |